Hyperfine's Model 2 Inflection: From Critical Care to Neurology Offices and Beyond

Q2 2026: A Turning Point in Commercial Execution

Hyperfine's second quarter delivered the strongest evidence yet that its Model 2 strategy is working. Revenue rose 45% year-over-year to $3.9M, system placements jumped 50% to 12 units, and gross margin clocked in at 50.7% — the fourth consecutive quarter above 50%.

Management attributes this momentum to a broader commercial footprint: hospital placements are expanding beyond critical care into emergency departments and clinics, neurology offices are adopting the system at a faster pace (now over a dozen offices), and international markets are beginning to contribute with the first Model 2 sales in Europe and the U.K.

From Niche to Platform

The company's pivot from a niche critical-care tool to a multi-vertical platform is now backed by clinical evidence. The PRIME study, presented at SAEM 2026, showed that portable MRI cut median order-to-scan time in the ED from 7.76 hours to 1.28 hours.

This evidence is increasingly shaping IDN-level conversations. The company sold Model 2 systems to several new health systems, including a first placement within one of the largest national IDNs. As Maria Sainz noted, these are early but critical proof points for enterprise-wide adoption.

We have broadened adoption across sites of care, increased IDN engagement, entered new geographies, expanded our clinical evidence, strengthened our balance sheet, and improved the financial profile of the business.

In the office market, the company is seeing high utilization and interest from adjacent use cases such as dementia screening and concierge medicine. The planned expansion to add contrast labeling is expected to be a major catalyst, broadening clinical utility and supporting dedicated CPT codes with higher reimbursement.

Financial Health Improves, Guidance Maintained

Hyperfine's balance sheet is in a better place than a year ago. The company raised $10.6M net via its ATM at $1.52 per share, ending Q2 with $43.5M in cash. Cash burn improved both year-over-year and sequentially, and management reaffirmed full-year guidance of $20–22M revenue, 50–55% gross margin, and $26–28M cash burn.

The company's price-to-revenue multiple, at 1.1x, reflects the market's cautious optimism despite early signs of a turnaround.

Catalysts Ahead: Contrast, Software, and International Rollout

Management laid out a clear set of second-half catalysts: the next FDA submission for contrast (enrollment in Contrast PMR is ~75% complete), a new AI-enabled software release, and continued international expansion, including the UniHA procurement listing in France and the AIIMS New Delhi reference site in India. The company also highlighted early interest in neurosurgical and mobile workflows.

Prior calls have emphasized the same themes — IDN budgetary cycles, office segmentation, and international execution — but the tone now is more concrete, with actual placements and evidence backing the narrative. As Maria noted in the Q1 call, "We have visibility to multiple sites within an IDN" — a statement that now has tangible validation.

The stock, down 91% from its 2021 peak and 25% over the last 90 days, still trades at a steep discount to the company's potential. But with sustained execution, a clear path to gross margin expansion, and a second-half weighted guidance, Hyperfine offers an intriguing risk/reward for investors willing to look past the current losses.